Quantum Biopharma (QNTM) Projected to Announce Quarterly Earnings on Friday

Quantum Biopharma (NASDAQ:QNTM) will likely be announcing its resultson Friday, November 6th. Analysts expect the company to post earnings of ($0.50) per share for the quarter.

Quantum Biopharma (NASDAQ:QNTM) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06).

Quantum Biopharma Price Performance

Shares of QNTM stock opened at $2.21 on Thursday. The stock’s 50-day moving average is $3.05 and its two-hundred day moving average is $3.83. Quantum Biopharma has a 1 year low of $2.07 and a 1 year high of $12.42.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on QNTM shares. Weiss Ratings downgraded Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Rodman & Renshaw assumed coverage on Quantum Biopharma in a research note on Monday, August 31st. They set a “buy” rating and a $8.00 price target on the stock. Finally, Wall Street Zen raised Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Quantum Biopharma Company Profile

Quantum BioPharma Ltd. is a biotechnology company focused on developing treatments for neurodegenerative and neurological disorders. Its lead drug candidate, Lucid-21-302, also known as Lucid-MS, is an orally administered small molecule being developed as a potential therapy for multiple sclerosis. The company is investigating the compound’s ability to protect nerve cells and promote remyelination, or the repair of damaged myelin.

Quantum BioPharma is also pursuing additional applications for its drug-development platform, including potential treatments for other neurodegenerative and mental health conditions.